A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma

Neuro-Oncology

Volumn 13, Issue 10, 2011, Pages 1143-1150

  Kreisl, Teri N ^a   Zhang, Weiting ^a   Odia, Yazmin ^a   Shih, Joanna H ^a   Butman, John A ^b   Hammoud, Dima ^b   Iwamoto, Fabio M ^a   Sul, Joohee ^a   Fine, Howard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anaplastic glioma; Bevacizumab; FDG; Perfusion MRI

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONFUSION; CONTRAST ENHANCEMENT; DECUBITUS; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; EPISTAXIS; FATIGUE; FEMALE; GLIOMA; HAND FOOT SYNDROME; HEMOGLOBINURIA; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LYMPHOCYTOPENIA; MALE; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIPHERAL EDEMA; PETECHIA; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECTUM HEMORRHAGE; RECURRENT ANAPLASTIC GLIOMA; RETINOPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR RECURRENCE; TUMOR VASCULARIZATION; TUMOR VOLUME; VOMITING; WOUND COMPLICATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80755159087     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor091     Document Type: Article

References (21)

1. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
2. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
3. Ali SA, McHayleh WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 2008;109(2):268-272.
4. Gil Gil MJ, Sr, Martinez-Garcia M, Reynes G, et al. Combination of bevacizumab plus irinotecan in recurrent malignant gliomas (MG): A retrospective study of efficacy and safety. ASCO Meeting Abstracts. 2008;26(15 suppl):13011.
5. Kang T, Jin T, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland Clinic experience. ASCO Meeting Abstracts. 2007;25(18 suppl):2077.
6. Narayana A, Chheang S, Knopp E, et al. Comparing cerebral blood volume and vascular permeability measurements with tumor volume measurements following anti-angiogenesis therapy in recurrent gliomas. ASCO Meeting Abstracts. 2007;25(18 suppl):2030.
7. Norden AD, Drappatz J, Muzikansky A, et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009;92(2):149-155.
8. Poulsen HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48(1):52-58.
9. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91(3):329-336.
10. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977;47(3):329-335. (Pubitemid 8170121)
11. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280. (Pubitemid 20195640)
12. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
13. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578. (Pubitemid 29368260)
14. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res. 1996;29(3):162-173. (Pubitemid 26266657)
15. Solomon J, Butman JA, Sood A. Segmentation of brain tumors in 4D MR images using the hidden Markov model. Comput Methods Programs Biomed. 2006;84(2-3):76-85. (Pubitemid 46053603)
16. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170.
17. Desjardins A, Reardon DA, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14(21):7068-7073.
18. Desjardins A, Barboriak DP, Herndon JE, II, et al. Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. ASCO Meeting Abstracts. 2008;26(15 suppl):2026.
19. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69(13):5296-5300.
20. Mitchell CL, O'Connor JP, Roberts C, et al. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol Epub 2010 Dec.
21. Notohamiprodjo M, Sourbron S, Staehler M, et al. Measuring perfusion and permeability in renal cell carcinoma with dynamic contrast-enhanced MRI: a pilot study. J Magn Reson Imaging. 2010;31(2):490-501.